Neoadjuvant PD-L1/TGF-β blockade can rapidly disrupt the tumor stroma in head and neck cancer patients.

In 30 seconds

This window-of-opportunity clinical study examined neoadjuvant bintrafusp alfa, a dual PD-L1 and TGF-β inhibitor, in patients with head and neck squamous cell carcinoma. Biopsies from six patients before treatment and three weeks after therapy were assessed using single-cell RNA sequencing, imaging, and spatial transcriptomics; findings were independently confirmed in another six treated patients. Treatment was associated with fewer activated LRRC15+ cancer-associated fibroblasts, reduced stromal collagen, and greater CD8+ T-cell infiltration in immune-excluded tumors. The study demonstrated rapid stromal disruption, but its final clinical cohort could not assess treatment effect.

Key findings

• In six patients, activated LRRC15+ cancer-associated fibroblasts decreased after three weeks of neoadjuvant bintrafusp alfa.
• Stromal architecture was remodeled, with reduced collagen I and XII content after treatment.
• CD8+ T-cell infiltration increased in immune-excluded tumors; these stromal changes were confirmed in an additional cohort of six patients.
• The reduction in fibroblasts and stromal compartment suggested fibroblast depletion rather than a shift in fibroblast polarization.

Why it matters

The findings show that targeting TGF-β alongside PD-L1 can alter the tumor microenvironment over a short interval in patients with head and neck cancer. Stromal remodeling and increased T-cell infiltration may be relevant to understanding immune exclusion and resistance to checkpoint blockade. The study also highlights the need for further trials and biomarkers to identify patients who may benefit.

What to keep in mind

The final clinical cohort did not allow assessment of treatment effect. The study involved small cohorts and short-term biopsy changes, rather than evidence of clinical benefit.